Biogen (BIIB) Competitors

$230.57
+0.53 (+0.23%)
(As of 05/17/2024 ET)

BIIB vs. AEP, NBIX, RGEN, PNW, CRSP, POR, DNLI, GILD, BNTX, and ARGX

Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include American Electric Power (AEP), Neurocrine Biosciences (NBIX), Repligen (RGEN), Pinnacle West Capital (PNW), CRISPR Therapeutics (CRSP), Portland General Electric (POR), Denali Therapeutics (DNLI), Gilead Sciences (GILD), BioNTech (BNTX), and argenx (ARGX).

Biogen vs.

Biogen (NASDAQ:BIIB) and American Electric Power (NASDAQ:AEP) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.

American Electric Power has higher revenue and earnings than Biogen. American Electric Power is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.84B3.41$1.16B$8.0128.79
American Electric Power$19B2.57$2.21B$5.3917.19

Biogen received 1698 more outperform votes than American Electric Power when rated by MarketBeat users. Likewise, 71.89% of users gave Biogen an outperform vote while only 55.40% of users gave American Electric Power an outperform vote.

CompanyUnderperformOutperform
BiogenOutperform Votes
1775
71.89%
Underperform Votes
694
28.11%
American Electric PowerOutperform Votes
77
55.40%
Underperform Votes
62
44.60%

American Electric Power has a net margin of 14.60% compared to Biogen's net margin of 12.07%. Biogen's return on equity of 14.83% beat American Electric Power's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen12.07% 14.83% 8.19%
American Electric Power 14.60%11.23%2.93%

Biogen currently has a consensus price target of $288.46, indicating a potential upside of 25.11%. American Electric Power has a consensus price target of $88.43, indicating a potential downside of 4.58%. Given Biogen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biogen is more favorable than American Electric Power.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
9 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.65
American Electric Power
2 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.38

Biogen has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, American Electric Power has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

In the previous week, Biogen had 5 more articles in the media than American Electric Power. MarketBeat recorded 29 mentions for Biogen and 24 mentions for American Electric Power. American Electric Power's average media sentiment score of 0.72 beat Biogen's score of 0.29 indicating that American Electric Power is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
7 Very Positive mention(s)
3 Positive mention(s)
16 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
American Electric Power
7 Very Positive mention(s)
6 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 75.2% of American Electric Power shares are held by institutional investors. 0.6% of Biogen shares are held by insiders. Comparatively, 0.1% of American Electric Power shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Biogen beats American Electric Power on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIIB vs. The Competition

MetricBiogenBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$33.57B$2.96B$5.17B$7.96B
Dividend YieldN/A2.18%44.01%3.91%
P/E Ratio28.7913.50118.4515.56
Price / Sales3.41377.552,367.4177.86
Price / Cash12.48160.8536.4531.98
Price / Book2.217.215.754.76
Net Income$1.16B-$43.47M$105.79M$217.17M
7 Day Performance4.09%4.26%1.39%2.90%
1 Month Performance21.02%9.96%4.28%6.57%
1 Year Performance-24.51%7.86%7.71%10.17%

Biogen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEP
American Electric Power
4.3295 of 5 stars
$90.79
-0.8%
$88.43
-2.6%
+6.4%$47.86B$19B16.8417,250Analyst Forecast
Short Interest ↑
NBIX
Neurocrine Biosciences
4.7111 of 5 stars
$138.48
+1.7%
$148.96
+7.6%
+49.4%$13.94B$1.89B38.151,400Analyst Forecast
Insider Selling
RGEN
Repligen
4.1069 of 5 stars
$172.48
+5.6%
$197.75
+14.7%
+12.4%$9.64B$638.76M689.951,783Positive News
PNW
Pinnacle West Capital
4.2798 of 5 stars
$77.00
+0.1%
$74.08
-3.8%
-0.1%$8.74B$4.70B16.786,133
CRSP
CRISPR Therapeutics
2.9796 of 5 stars
$55.71
+0.1%
$73.93
+32.7%
-12.7%$4.73B$270M-20.48473Gap Up
POR
Portland General Electric
1.6691 of 5 stars
$44.27
-1.1%
$43.57
-1.6%
-10.4%$4.56B$2.92B16.962,842Analyst Forecast
News Coverage
DNLI
Denali Therapeutics
4.2104 of 5 stars
$19.75
+2.3%
$40.22
+103.7%
-31.0%$2.82B$295.39M-20.57445Short Interest ↑
GILD
Gilead Sciences
4.8801 of 5 stars
$67.65
+0.2%
$83.69
+23.7%
-14.1%$84.28B$27.45B187.9218,000
BNTX
BioNTech
1.4212 of 5 stars
$92.28
-0.5%
$118.82
+28.8%
-13.8%$21.94B$4.13B184.566,133Analyst Forecast
Short Interest ↑
ARGX
argenx
2.9527 of 5 stars
$356.01
-1.0%
$524.68
+47.4%
-11.4%$21.16B$1.27B-62.901,148Earnings Report
Short Interest ↑

Related Companies and Tools

This page (NASDAQ:BIIB) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners